ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1382

Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome

(1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1427

Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials

(1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

9:00AM-11:00AM: Abstract Number: 1322

Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 0988

Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1315

Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1497

Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications

(1488–1512) SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1025

Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients

(1013–1032) Healthcare Disparities in Rheumatology Poster II: Socioeconomic Determinants

9:00AM-11:00AM: Abstract Number: 1095

Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1049

Enhanced Diagnostic Confidence with High Frequency Temporal Artery Ultrasound in Diagnosis of Cranial Giant Cell Arteritis (GCA)

(1033–1051) Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0868

Enhancing Oxidative Phosphorylation Through PDK2 Depletion Alleviates Cartilage Degradation in Surgically Induced Osteoarthritis

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1546

Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus

(1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

9:00AM-11:00AM: Abstract Number: 1552

Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France

(1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

9:00AM-11:00AM: Abstract Number: 1535

Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study

(1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

9:00AM-11:00AM: Abstract Number: 0907

Epstein Barr Virus Reactivation May Associate with Transition from Incomplete to Systemic Lupus Erythematosus

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1115

EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice

(1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].